Long-Acting Muscarinic Antagonists (Lama) In Chronic Obstructive Pulmonary Disease (Copd): A Rare Events Meta Analysis Of Clinically Relevant Adverse Events

Abstract

study was to evaluate these PQA measures and assess predictors of qualifying into these measures among Medicaid beneficiaries from 39 states in the US. Methods: Medicaid beneficiaries from 39 US states aged 5 to 50 years were identified in calendar year 2008. Of these, beneficiaries who filled one or more prescriptions for COPD medications, dornase alfa, or nasal steroid medications were excluded from the analysis. Beneficiaries with at least three canisters of short-acting beta agonists within 90 days were identified as those with SAC. Of the beneficiaries with SAC, those who did not receive asthma controller therapy in the same 90 day period were identified as those with ACT.